United Therapeutics Corporation Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost
United Therapeutics Corporation (UTHR) had Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost of $1.93 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Debt and Equity Securities › Available-for-Sale Securities, Debt Maturities
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $1.93B.
- 2026-03-31: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $2.13B.
- 2025-12-31: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $3.04B.
- 2025-09-30: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $3.01B.
| Period end | Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost |
|---|---|
| 2026-06-30 | $1.93B 10-Q · filed 2026-08-05 |
| 2026-03-31 | $2.13B 10-Q · filed 2026-05-06 |
| 2025-12-31 | $3.04B 10-K · filed 2026-02-25 |
| 2025-09-30 | $3.01B 10-Q · filed 2025-10-29 |
| 2025-06-30 | $3.77B 10-Q · filed 2025-07-30 |
| 2025-03-31 | $3.27B 10-Q · filed 2025-04-30 |
| 2024-12-31 | $3.04B 10-K · filed 2025-02-26 |
| 2024-09-30 | $3.02B 10-Q · filed 2024-10-30 |
| 2024-06-30 | $2.97B 10-Q · filed 2024-07-31 |
| 2024-03-31 | $2.99B 10-Q · filed 2024-05-01 |
| 2023-12-31 | $3.77B 10-K · filed 2024-02-21 |
| 2023-09-30 | $3.88B 10-Q · filed 2023-11-01 |
| 2023-06-30 | $3.69B 10-Q · filed 2023-08-02 |
| 2023-03-31 | $3.51B 10-Q · filed 2023-05-03 |
| 2022-12-31 | $3.25B 10-K · filed 2023-02-22 |
| 2022-09-30 | $3.22B 10-Q · filed 2022-11-02 |
| 2022-06-30 | $3.16B 10-Q · filed 2022-08-03 |
| 2022-03-31 | $2.99B 10-Q · filed 2022-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |